Maryland HB1477 establishes a grant program for clinical research on ibogaine, a psychoactive compound, for treating opioid use disorder and other.

Maryland HB1477 creates the Ibogaine Clinical Research Grant Program, which provides grants to eligible research institutions within the state. These institutions must have a history of research and treatment of neurological diseases and expertise in substance use disorder, post-traumatic stress disorder, or trauma. The grants are intended for conducting certified clinical drug development trials overseen by the U.S. Food and Drug Administration on the use of ibogaine for treating opioid use disorder and other neurological conditions.

Maryland HB1477 establishes a grant program for clinical research on ibogaine, a psychoactive compound, for treating opioid use disorder and other.

Maryland HB1477 creates the Ibogaine Clinical Research Grant Program, which provides grants to eligible research institutions within the state. These institutions must have a history of research and treatment of neurological diseases and expertise in substance use disorder, post-traumatic stress disorder, or trauma. The grants are intended for conducting certified clinical drug development trials overseen by the U.S. Food and Drug Administration on the use of ibogaine for treating opioid use disorder and other neurological conditions.